ImmunityBio stock rose 2% in overnight trading. The company faces a May 18, 2026, FDA workshop regarding its lead immunotherapy, Anktiva. This meeting will evaluate the drug's expansion into different forms of bladder cancer. Founder Patrick Soon-Shiong described the upcoming session as pivotal for the drug’s regulatory path.
The company signed an exclusive U.S. agreement with Japan BCG Laboratory on May 16, 2026. ImmunityBio secured rights to develop and commercialize the Tokyo strain of BCG. This strategic move addresses a decade-long domestic shortage of the bladder cancer therapy. The deal establishes a second potential supply source for the company.